Novo Nordisk touts late-stage trial data for Tresiba insulin injection

Novo Nordisk (NYSE:NVO) touted data today from 2 Phase IIIb trials comparing Tresiba insulin degludec to insulin glargine in adults with Type I and Type II diabetes.

The results were published in the Journal of  the American Medical Association.

The Switch trials are the 1st double-blinded insulin trials to compare the hypoglycemia rates and risks in patients using Tresiba and insulin glargine for Type I diabetes and Type II diabetes.

Get the full story at our sister site, Drug Delivery Business News.

The post Novo Nordisk touts late-stage trial data for Tresiba insulin injection appeared first on MassDevice.

from MassDevice http://ift.tt/2tjxqOk